Physician Assessment of Treatment

Materials for Network Members

Administering BOTOX^® Cosmetic

Clinical Information

	Physician Assessment
	Patient Assessment
	No Downtime
	Mode of Action
	Slide Kits

Professional Organizations

Information for Consumers

Results You Can See...

Significant improvement in glabellar lines vs placebo^1,2

Physicians' rating of glabellar line severity at maximum frown^1,2

BOTOX^® Cosmetic: n=405; Placebo: n=132
Data from a 4-month, double-blind, placebo-controlled study period.

*During this period, the responder rate was significantly greater for the BOTOX^® Cosmetic group compared with the placebo group at all time periods (P<0.001).

Maximum responder rate was 80% on Day 30, with a majority of patients (74%) showing response by Day 7 (n=405)^1,2
25% of patients treated with BOTOX^® Cosmetic continued to be responders at Day 120 (n=403)^1,2

Physicians' rating of glabellar line severity at rest^1,2

BOTOX^® Cosmetic: n=405; Placebo: n=132
Data from a 4-month, double-blind, placebo-controlled study period.

*During this period, the responder rate was significantly greater for the BOTOX^® Cosmetic group compared with the placebo group at all time periods (P<0.001).

Maximum responder rate was 80% on Day 30, with a majority of patients (74%) showing response by Day 7 (n=405)^1,2
25% of patients treated with BOTOX^® Cosmetic continued to be responders at Day 120 (n=403)^1,2

1. BOTOX^® Cosmetic [package insert]. Irvine, Calif: Allergan, Inc; 2002.
2. Data on file, Allergan.

BOTOX^® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in patients 18 to 65 years of age.

Important Safety Information

BOTOX^® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation. There have been rare reports of adverse events involving the cardiovascular system. Serious and/or immediate hypersensitivity reactions have been reported rarely. These reactions include anaphylaxis, urticaria, soft-tissue edema, and dyspnea.

The most common adverse events following injection include blepharoptosis and nausea. Localized pain, infection, inflammation, tenderness, swelling, erythema and/or bleeding/bruising may be associated with the injection. Patients with neuromuscular disorders such as ALS, myasthenia gravis, or Lambert-Eaton syndrome may be at increased risk of serious adverse events.

Please see the additional safety information and full prescribing information.

Home | Prescribing Information | Privacy Policy | Contact Allergan | Site Map